Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings
About Harbin Pharmaceutical Group Co.,Ltd.
Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 2025年度独立董事述职报告—娄爱东 | 2026-04-22 | Chinese | |
| 哈药集团股份有限公司董事及高级管理人员薪酬管理与履职评价制度(2026年4月) | 2026-04-22 | Chinese | |
| 哈药集团股份有限公司股票交易异常波动公告 | 2026-04-15 | Chinese | |
| 哈药集团有限公司关于哈药集团股份有限公司股票交易异常波动询证函的回复 | 2026-04-15 | Chinese | |
| 哈药集团股份有限公司十届二十四次董事会决议公告 | 2026-03-09 | Chinese | |
| 哈药集团股份有限公司关于所属企业药品通过仿制药一致性评价的公告 | 2026-02-10 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 41340165 | 2025年度独立董事述职报告—娄爱东 | 2026-04-22 | Chinese | ||
| 41340163 | 哈药集团股份有限公司董事及高级管理人员薪酬管理与履职评价制度(2026年4月) | 2026-04-22 | Chinese | ||
| 41340161 | 哈药集团股份有限公司股票交易异常波动公告 | 2026-04-15 | Chinese | ||
| 41340153 | 哈药集团有限公司关于哈药集团股份有限公司股票交易异常波动询证函的回复 | 2026-04-15 | Chinese | ||
| 41340146 | 哈药集团股份有限公司十届二十四次董事会决议公告 | 2026-03-09 | Chinese | ||
| 41340138 | 哈药集团股份有限公司关于所属企业药品通过仿制药一致性评价的公告 | 2026-02-10 | Chinese | ||
| 41340128 | 哈药集团股份有限公司关于所属企业获得化学原料药上市申请批准通知书的公告 | 2026-02-05 | Chinese | ||
| 41340114 | 哈药集团股份有限公司关于所属企业药品通过仿制药一致性评价的公告 | 2026-02-04 | Chinese | ||
| 41340100 | 哈药集团股份有限公司关于所属企业获得药品注册证书的公告 | 2026-02-02 | Chinese | ||
| 41340094 | 哈药集团股份有限公司关于2026年度日常关联交易预计的公告 | 2026-01-26 | Chinese | ||
| 41340083 | 哈药集团股份有限公司十届二十三次董事会决议公告 | 2026-01-26 | Chinese | ||
| 41340076 | 哈药集团股份有限公司关于变更质量控制复核人的公告 | 2026-01-21 | Chinese | ||
| 41340066 | 哈药集团股份有限公司关于变更签字注册会计师、质量控制复核人的公告 | 2026-01-07 | Chinese | ||
|
2025
2 filings
| |||||
| 41340057 | 哈药集团股份有限公司董事会战略与可持续发展委员会工作细则(2025年12月) | 2025-12-24 | Chinese | ||
| 41340055 | 哈药集团股份有限公司十届二十二次董事会决议公告 | 2025-12-24 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
|
Adaptimmune Therapeutics PLC
Commercial-stage biopharma developing TCR T-cell therapies …
|
ADAP | GB | Manufacturing |
Harbin Pharmaceutical Group Co.,Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56904/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56904 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56904 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56904 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56904}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Harbin Pharmaceutical Group Co.,Ltd. (id: 56904)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.